A microfluidic manufacturing approach from researchers at The Second Qilu Hospital of Shandong University boosted CAR T cell transduction at low viral doses, aiming to shorten and streamline production for CD19-targeting therapies. By tightening the core manufacturing timeline while maintaining key functional properties, the method targets a persistent bottleneck for CAR T scaling: time, cost, and sensitivity to process parameters.